Short Communication

Yeast Hydrolysate Protects Cartilage via Stimulation of Type II Collagen Synthesis and Suppression of MMP-13 Production

  1. Hyun-Sun Lee1,
  2. So Yeon Park1,
  3. Yooheon Park1,
  4. Song Hwan Bae2,
  5. Hyung Joo Suh1,*

Article first published online: 16 OCT 2012

DOI: 10.1002/ptr.4857

Additional Information

How to Cite

Lee, H.-S., Park, S. Y., Park, Y., Bae, S. H. and Suh, H. J. (2012), Yeast Hydrolysate Protects Cartilage via Stimulation of Type II Collagen Synthesis and Suppression of MMP-13 Production. Phytother. Res.. doi: 10.1002/ptr.4857

Author Information

  1. 1

    Department of Food and Nutrition, Korea University, Seoul, Korea

  2. 2

    Department of Food and Biotechnology, Hankyong National University, Anseong, Korea

* Professor Hyung Joo Suh, Department of Food and Nutrition, Korea University, 1 Jeongneung-dong, Sungbuk-ku, Seoul 136-703, Korea.
E-mail: suh1960@korea.ac.kr

Publication History

  1. Article first published online: 16 OCT 2012
  2. Manuscript Accepted: 17 SEP 2012
  3. Manuscript Revised: 21 AUG 2012
  4. Manuscript Received: 26 MAR 2012

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (317K)

Keywords:

  • yeast hydrolysate;
  • arthritis;
  • rabbit chondrocyte;
  • type II collagen;
  • interleukin-1β;
  • metalloproteases-13

Type II collagen (COL II) is one of the primary components of hyaline cartilage and plays a key role in maintaining chondrocyte function. COL II is the principal target of destruction, and matrix metalloproteases (MMPs) have a major role in arthritis. In the present study, we investigated the chondroctye protection effects of specific fraction of yeast hydrolysate ((10–30 kDa molecular weight peptides). The mRNA expression of COL II was significantly increased in the YH-treated group compared to the control at concentrations above 50 µg/ml, respectively. The 200 µg/ml YH-treated group (3.43 ± 0.23 µg/ml) showed significantly reduced glycosaminoglycan (GAG) degradation relative to that in the interleukin-1β (IL-1β)-treated control group (4.72 ± 0.05 µg/ml). In the YH-treated group, MMP-13 level was significantly decreased in a dose-dependent manner compared to the IL-1β-treated group without YH treatment. However, MMP-1 and MMP-3 level were not different from that of control. Under the same conditions, we also examined mRNA levels of COL II. The mRNA expression of COL II was significantly higher in the YH-treated group than in the IL-1β-treated control group at concentrations above 100 µg/ml. In conclusion, YH stimulated COL II synthesis and significantly inhibited MMP-13 and GAG degradation caused by IL-1β treatment. Copyright © 2012 John Wiley & Sons, Ltd.

View Full Article (HTML) Get PDF (317K)